Pain and genetics

Current Opinion in Anaesthesiology

Volumn 25, Issue 4, 2012, Pages 444-449

  Fernandez Robles, Claudia R ^a   Degnan, Meredith ^b   Candiotti, Keith A ^a,b  

^a JACKSON MEMORIAL HOSPITAL   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

genetics; opioids; pain; pharmacogenomics

Indexed keywords

ADRENALIN; ANALGESIC AGENT; ATP BINDING CASSETTE SUBFAMILY B1; CATECHOL METHYLTRANSFERASE; CODEINE; CYTOCHROME P450 2D6; DELTA OPIATE RECEPTOR; DOPAMINE; FENTANYL; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; KAPPA OPIATE RECEPTOR; MELANOCORTIN 1 RECEPTOR; MEMBRANE PROTEIN; MORPHINE; MU 1 OPIATE RECEPTOR; MU OPIATE RECEPTOR; NORADRENALIN; OXALIPLATIN; OXYCODONE; OXYMORPHONE; PARACETAMOL PLUS TRAMADOL; SUFENTANIL; TRAMADOL; UNCLASSIFIED DRUG;

ALLELE; ANALGESIA; ANALGESIC ACTIVITY; AREA UNDER THE CURVE; BURN; CANCER PAIN; ELECTRIC SHOCK; ENZYME ACTIVITY; EXON; FATIGUE; GENERAL ANESTHESIA; GENETIC VARIABILITY; GENETICS; GENOTYPE; HUMAN; HYSTERECTOMY; INTRON; MASTECTOMY; MYOMECTOMY; NEUROPATHY; NOCICEPTION; NONHUMAN; OSTEOARTHRITIS; PAIN; PAIN THRESHOLD; PHARMACOGENOMICS; PREGNANT WOMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SEDATION; SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE; WILD TYPE;

ANIMALS; CATECHOL O-METHYLTRANSFERASE; CYTOCHROME P-450 CYP2D6; HUMANS; INDIVIDUALIZED MEDICINE; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; P-GLYCOPROTEIN; PAIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, MELANOCORTIN, TYPE 1; RECEPTORS, OPIOID, MU;

EID: 84863793670     PISSN: 09527907     EISSN: 14736500     Source Type: Journal    
DOI: 10.1097/ACO.0b013e3283556228     Document Type: Review

References (41)

1. Body SC. Genomics: Implications for anesthesia, perioperative care and outcomes. Adv Anesth 2009; 27:73-94.
2. Mirnezamim R, Nicholson J, Darzi A. Preparing for precision medicine. N Engl J Med 2012; 366:489-491.
3. Candiotti KA. Anesthesia and pharmacogenomics: not ready for prime time. Anesth Analg 2009; 109:1377-1378.
4. Schumacher MA, Basbaum AI, Way WL. Opioid analgesics and antagonists. In: Katzung BG, editor. Basic and clinical pharmacology. 10th ed. New York: McGraw-Hill; 2006. pp. 492.
5. Sehgal N, Smith HS, Manchikanti L. Peripherally acting opioids and clinical implications for pain control. Pain Physician 2011; 14:249-258.
6. Liu YC, Wang WS. Human mu-opioid receptor gene A118G polymorphism predicts the efficacy of tramadol/acetaminophen combination tablets (Ultracet) in oxaliplatin-induced painful neuropathy cancer. Cancer 2012; 118:1718-1725.
7. Chou WY, Wang CH, Liu PH, et al. Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology 2006; 105:334-337.
8. Kleine-Brueggeney M, Musshoff F, Stuber F, Stamer U. Pharmacogenetics in palliative care. Forensic Sci Int 2010; 203:63-70.
9. Kosarac B, Fox A, Collard C. Effect of genetic factors on opioid action. Curr Opin Anaesthesiol 2009; 22:476-482.
10. Zwisler ST, Enggaard TP, Mikkelsen S, et al. Lack of association of OPRM1 and ABCB1 single nucleotide polymorphisms to oxycodone response in postoperative pain. J Clin Pharmacol 2012; 52:234-242.
11. Camorcia M, Capogna G, Stirparo S, et al. Effect of l-opioid receptor A118G polymorphism on the ED50 of epidural sufentanil for labor analgesia. Int J Obstet Anesth 2012; 21:40-44.
12. Zhang W, Chang YZ, Kan QC, et al. Association of human m-opioid receptor gene polymorphism A118G with fentanyl analgesia consumption in Chinese gynaecological patients. Anaesthesia 2010; 65:130-135.
13. Walter C, Lötsch J. Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment. Pain 2009; 146:270-275.
14. Shi Q, Cleeland CS, Klepstad P, et al. Biological pathways and genetic variables involved in pain. Qual Life Res 2010; 19:1407-1417.
15. Campa D, Gioia A, Tomei A, et al. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther 2008; 83:559-566.
16. Lötsch J, von Hentig N, Freynhagen R, et al. Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenet Genomics 2009; 19:429-436.
17. Zwisler ST, Enggaard TP, Noehr-Jensen L, et al. The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes. Fundam Clin Pharmacol 2010; 24:517-524.
18. Rakva'g TT, Klepstad P, Baar C, et al. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 2005; 116:73-78.
19. Loggia ML, Jensen K, Gollub RL, et al. The catechol-o-methyltransferase (COMT) val158met polymorphismaffects brain responses to repeated painful stimuli. PLoS One 2011; 6:e27764.
20. Zubieta JK, Heitzeg MM, Smith YR, et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 2003; 299:1240-1243.
21. Mobascher A, Brinkmeyer J, Thiele H, et al. The val158met polymorphism of human catechol-O-methyltransferase (COMT) affects anterior cingulate cortex activation in response to painful laser stimulation. Mol Pain 2010; 6:32.
22. Jensen KB, Lonsdorf TB, Schalling M, et al. Increased Sensitivity to Thermal Pain Following a Single Opiate Dose Is Influenced by the COMT val158met Polymorphism. PLoS One 2009; 4:e6016.
23. HickeyOT, Nugent NF, Burke SM, et al. Persistent pain after mastectomy with reconstruction. J Clin Anesth 2011; 23:482-488.
24. Fernández-De-Las-Peñas C, Fernández-Lao C, Cantarero-Villanueva I, et al. Catechol-O-methyltransferase genotype (Val158met) modulates cancerrelated fatigue and pain sensitivity in breast cancer survivors. Breast Cancer Res Treat 2012; 133:405-412.
25. Orrey DC, Bortsov AV, Hoskins JM, et al. Catechol-O-methyltransferase genotype predicts pain severity in hospitalized burn patients. J Burn Care Res 2012. [Epub ahead of print]
26. Lee PJ, Delaney P, Keogh J, et al. Catecholamine-O-methyltransferase polymorphisms are associated with postoperative pain intensity. Clin J Pain 2011; 27:93-101.
27. Diatchenko L, Slade GD, Nackley AG, et al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet 2005; 14:135-143.
28. Rakva'g TT, Ross JR, Sato H, et al. Genetic variation in the catechol-O-methyltransferase (COMT) gene and morphine requirements in cancer patients with pain. Mol Pain 2008; 4:64.
29. Leppert W. CYP2D6 in the metabolism of opioids for mild to moderate pain. Pharmacology 2011; 87:274-285.
30. Mikus G, Weiss J. Influence of CYP2D6 genetics on opioid kinetics, metabolism and response. Curr Pharmacogenomics 2005; 3:43-52.
31. Candiotti KA, Yang Z, Rodriguez Y, et al. The impact of CYP2D6 genetic polymorphism on postoperative morphine pain relief. Pain Med 2009; 10:799-805.
32. Samer CF, Daali Y, Wagner M, et al. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. Br J Pharmacol 2010; 160:919-930.
33. Andreassen TN, Eftedal I, Klepstad P, et al. Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A crosssectional multicentre study. Eur J Clin Pharmacol 2012; 68:55-64.
34. Kirchheiner J, Schmidt H, Tzvetkov M, et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 2007; 7:257-265.
35. Bessler H, Shavit Y, Mayburd E, et al. Postoperative pain, morphine, consumption and genetic polymorphism of IL-1b and IL-1 receptor antagonist. Neurosci Lett 2006; 404 (1-2):154-158.
36. Candiotti K, Yang Z, Morris R, et al. Polymorphism in the interleukin-1 receptor antagonist gene is associated with serum interleukin-1 receptor antagonist concentrations and postoperative opioid consumption. Anesthesiology 2011; 114:1162-1168.
37. AtturM, Belitskaya-Lévy I, Oh C, et al. Increased interleukin-1 gene expression in peripheral blood leukocytes is associated with increased pain and predicts risk for progression of symptomatic knee osteoarthritis. Arthritis Rheum 2011; 63:1908-1917.
38. Cohen SB, Proudman S, Kivitz AJ, et al. A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee. Arthritis Res Ther 2011; 13:R125.
39. Mogil JS, Wilson SG, Chesler EJ, et al. The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans. Proc Natl Acad Sci U S A 2003; 100:4867-4872.
40. Mogil JS, Ritchie J, Smith SB, et al. Melanocortin-1 receptor gene variants affect pain and mu-opioid analgesia in mice and humans. J Med Genet 2005; 42:583-587.
41. Delaney A, Keighren M, Fleetwood-Walker SM, Jackson IJ. Involvement of the melanocortin-1 receptor in acute pain and pain of inflammatory but not neuropathic origin. PLoS One 2010; 5:e12498.